Lung Cancer Therapeutics Market Size, Growth, Demands Outlook and Forecasts to 2030

According to the research report, the global lung cancer therapeutics market size is expected to touch USD 55.6 Billion by 2030, from USD 29.8 Billion in 2022, growing with a significant CAGR of 8.11% from 2022 to 2030. 

The lung cancer therapeutics report offers a comprehensive study of the current state expected at the major drivers, market strategies, and key vendors’ growth. The report presents energetic visions to conclude and study the market size, market hopes, and competitive surroundings. The research also focuses on the important achievements of the market, research & development, and regional growth of the leading competitors operating in the market. The current trends of the global lung cancer therapeutics in conjunction with the geographical landscape of this vertical have also been included in this report.

The report offers intricate dynamics about different aspects of the global lung cancer therapeutics market, which aids companies operating in the market in making strategic development decisions. The study also elaborates on significant changes that are highly anticipated to configure growth of the global lung cancer therapeutics during the forecast period. It also includes a key indicator assessment that highlights growth prospects of this market and estimates statistics related to growth of the market in terms of value (US$ Mn) and volume (tons).

Sample Link @ https://www.precedenceresearch.com/sample/1659

 Report Scope of the Lung Cancer Therapeutics Market

Report Coverage	Details
Market Size by 2030	USD 55.6 Billion
Growth Rate from 2022 to 2030	CAGR of 8.11%
Largest Market	North America
Fastest Growing Makret	Asia Pacific
Base Year	2021
Forecast Period	2022 to 2030
Segments Covered	Therapy, Lung Cancer Type, Distribution Channel, Drug Class, Type of Molecule, Geography

This study covers a detailed segmentation of the global lung cancer therapeutics market, along with key information and a competition outlook. The report mentions company profiles of players that are currently dominating the global lung cancer therapeutics market, wherein various developments, expansions, and winning strategies practiced and implemented by leading players have been presented in detail.

Key Players

• AstraZeneca
• BoehringerIngelheim
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• Hoffmann-La Roche
• Merck & Co
• Pfizer Inc.
• Allergan Inc.
• TevaPharmaceutical Industries Ltd.
• Abbvie, Inc.
• Johnson & Johnson
• Amgen Inc.
• Novartis AG

Market Segmentation

 By Therapy

• Radiation Therapy
• External Beam
• Internal Beam
• Systemic
• Targeted Therapy
• Bevacizumab
• Dabrafenib/Trametinib
• Erlotinib Hydrochloride
• Osimertinib
• Others
• Immunotherapy
• Durvalumab
• Nivolumab
• Atezolizumab
• Pembrolizumab
• Chemotherapy
• Others

By Lung Cancer Type

• Small Cell Lung Cancer
• Non-small Cell Lung Cancer
• Lung Carcinoid Tumor

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Type of Molecule

• Small molecules
• Biologics

By Drug Class

• Alkylating Agents
• Antimetabolites
• EGFR Inhibitors
• Mitotic Inhibitors
• Multikinase Inhibitors
• Others

By Geography

• North America
• U.S.
• Canada
• Europe
• U.K.
• Germany
• France
• Asia-Pacific
• China
• India
• Japan
• South Korea
• Malaysia
• Philippines
• Latin America
• Brazil
• Rest of Latin America
• Middle East & Africa (MEA)
• GCC
• North Africa
• South Africa
• Rest of the Middle East & Africa

Research Methodology

The research methodology adopted by analysts for compiling the global lung cancer therapeutics report is based on detailed primary as well as secondary research. With the help of in-depth insights of the market-affiliated information that is obtained and legitimated by market-admissible resources, analysts have offered riveting observations and authentic forecasts for the global market.

During the primary research phase, analysts interviewed market stakeholders, investors, brand managers, vice presidents, and sales and marketing managers. Based on data obtained through interviews of genuine resources, analysts have emphasized the changing scenario of the global market.

For secondary research, analysts scrutinized numerous annual report publications, white papers, market association publications, and company websites to obtain the necessary understanding of the global lung cancer therapeutics market.

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Lung Cancer Therapeutics Market 

5.1. COVID-19 Landscape: Lung Cancer Therapeutics Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Lung Cancer Therapeutics Market, By Therapy Type

8.1. Lung Cancer Therapeutics Market, by Therapy Type, 2022-2030

8.1.1. Radiation Therapy

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. Targeted Therapy

8.1.2.1. Market Revenue and Forecast (2017-2030)

8.1.3. Immunotherapy

8.1.3.1. Market Revenue and Forecast (2017-2030)

8.1.4. Chemotherapy

8.1.4.1. Market Revenue and Forecast (2017-2030)

8.1.5. Others

8.1.5.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Lung Cancer Therapeutics Market, By Lung Cancer Type

9.1. Lung Cancer Therapeutics Market, by Lung Cancer Type, 2022-2030

9.1.1. Small Cell Lung Cancer

9.1.1.1. Market Revenue and Forecast (2017-2030)

9.1.2. Non-small Cell Lung Cancer

9.1.2.1. Market Revenue and Forecast (2017-2030)

9.1.3. Lung Carcinoid Tumor

9.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Lung Cancer Therapeutics Market, By Distribution Channel Type 

10.1. Lung Cancer Therapeutics Market, by Distribution Channel Type, 2022-2030

10.1.1. Hospital Pharmacies

10.1.1.1. Market Revenue and Forecast (2017-2030)

10.1.2. Retail Pharmacies

10.1.2.1. Market Revenue and Forecast (2017-2030)

10.1.3. Online Pharmacies

10.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global Lung Cancer Therapeutics Market, By Type of Molecule

11.1. Lung Cancer Therapeutics Market, by Type of Molecule, 2022-2030

11.1.1. Small molecules

11.1.1.1. Market Revenue and Forecast (2017-2030)

11.1.2. Biologics

11.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 12. Global Lung Cancer Therapeutics Market, By Drug Class

12.1. Lung Cancer Therapeutics Market, by Drug Class, 2022-2030

12.1.1. Alkylating Agents

12.1.1.1. Market Revenue and Forecast (2017-2030)

12.1.2. Antimetabolites

12.1.2.1. Market Revenue and Forecast (2017-2030)

12.1.3. Multikinase Inhibitors

12.1.3.1. Market Revenue and Forecast (2017-2030)

12.1.4. Mitotic Inhibitors

12.1.4.1. Market Revenue and Forecast (2017-2030)

12.1.5. EGFR Inhibitors

12.1.5.1. Market Revenue and Forecast (2017-2030)

12.1.6. Others

12.1.6.1. Market Revenue and Forecast (2017-2030)

Chapter 13. Global Lung Cancer Therapeutics  Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Forecast, by Therapy (2017-2030)

13.1.2. Market Revenue and Forecast, by Lung Cancer (2017-2030)

13.1.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.1.4. Market Revenue and Forecast, by Type of Molecule (2017-2030)

13.1.5. Market Revenue and Forecast, by Drug Class (2017-2030)

13.1.6. U.S.

13.1.6.1. Market Revenue and Forecast, by Therapy (2017-2030)

13.1.6.2. Market Revenue and Forecast, by Lung Cancer (2017-2030)

13.1.6.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.1.6.4. Market Revenue and Forecast, by Type of Molecule (2017-2030)

13.1.7. Market Revenue and Forecast, by Drug Class (2017-2030) 

13.1.8. Rest of North America

13.1.8.1. Market Revenue and Forecast, by Therapy (2017-2030)

13.1.8.2. Market Revenue and Forecast, by Lung Cancer (2017-2030)

13.1.8.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.1.8.4. Market Revenue and Forecast, by Type of Molecule (2017-2030)

13.1.8.5. Market Revenue and Forecast, by Drug Class (2017-2030)

13.2. Europe

13.2.1. Market Revenue and Forecast, by Therapy (2017-2030)

13.2.2. Market Revenue and Forecast, by Lung Cancer (2017-2030)

13.2.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.2.4. Market Revenue and Forecast, by Type of Molecule (2017-2030) 

13.2.5. Market Revenue and Forecast, by Drug Class (2017-2030) 

13.2.6. UK

13.2.6.1. Market Revenue and Forecast, by Therapy (2017-2030)

13.2.6.2. Market Revenue and Forecast, by Lung Cancer (2017-2030)

13.2.6.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.2.7. Market Revenue and Forecast, by Type of Molecule (2017-2030) 

13.2.8. Market Revenue and Forecast, by Drug Class (2017-2030) 

13.2.9. Germany

13.2.9.1. Market Revenue and Forecast, by Therapy (2017-2030)

13.2.9.2. Market Revenue and Forecast, by Lung Cancer (2017-2030)

13.2.9.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.2.10. Market Revenue and Forecast, by Type of Molecule (2017-2030)

13.2.11. Market Revenue and Forecast, by Drug Class (2017-2030)

13.2.12. France

13.2.12.1. Market Revenue and Forecast, by Therapy (2017-2030)

13.2.12.2. Market Revenue and Forecast, by Lung Cancer (2017-2030)

13.2.12.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.2.12.4. Market Revenue and Forecast, by Type of Molecule (2017-2030)

13.2.13. Market Revenue and Forecast, by Drug Class (2017-2030)

13.2.14. Rest of Europe

13.2.14.1. Market Revenue and Forecast, by Therapy (2017-2030)

13.2.14.2. Market Revenue and Forecast, by Lung Cancer (2017-2030)

13.2.14.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.2.14.4. Market Revenue and Forecast, by Type of Molecule (2017-2030)

13.2.15. Market Revenue and Forecast, by Drug Class (2017-2030)

13.3. APAC

13.3.1. Market Revenue and Forecast, by Therapy (2017-2030)

13.3.2. Market Revenue and Forecast, by Lung Cancer (2017-2030)

13.3.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.3.4. Market Revenue and Forecast, by Type of Molecule (2017-2030)

13.3.5. Market Revenue and Forecast, by Drug Class (2017-2030)

13.3.6. India

13.3.6.1. Market Revenue and Forecast, by Therapy (2017-2030)

13.3.6.2. Market Revenue and Forecast, by Lung Cancer (2017-2030)

13.3.6.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.3.6.4. Market Revenue and Forecast, by Type of Molecule (2017-2030)

13.3.7. Market Revenue and Forecast, by Drug Class (2017-2030)

13.3.8. China

13.3.8.1. Market Revenue and Forecast, by Therapy (2017-2030)

13.3.8.2. Market Revenue and Forecast, by Lung Cancer (2017-2030)

13.3.8.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.3.8.4. Market Revenue and Forecast, by Type of Molecule (2017-2030)

13.3.9. Market Revenue and Forecast, by Drug Class (2017-2030)

13.3.10. Japan

13.3.10.1. Market Revenue and Forecast, by Therapy (2017-2030)

13.3.10.2. Market Revenue and Forecast, by Lung Cancer (2017-2030)

13.3.10.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.3.10.4. Market Revenue and Forecast, by Type of Molecule (2017-2030)

13.3.10.5. Market Revenue and Forecast, by Drug Class (2017-2030)

13.3.11. Rest of APAC

13.3.11.1. Market Revenue and Forecast, by Therapy (2017-2030)

13.3.11.2. Market Revenue and Forecast, by Lung Cancer (2017-2030)

13.3.11.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.3.11.4. Market Revenue and Forecast, by Type of Molecule (2017-2030)

13.3.11.5. Market Revenue and Forecast, by Drug Class (2017-2030)

13.4. MEA

13.4.1. Market Revenue and Forecast, by Therapy (2017-2030)

13.4.2. Market Revenue and Forecast, by Lung Cancer (2017-2030)

13.4.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.4.4. Market Revenue and Forecast, by Type of Molecule (2017-2030)

13.4.5. Market Revenue and Forecast, by Drug Class (2017-2030)

13.4.6. GCC

13.4.6.1. Market Revenue and Forecast, by Therapy (2017-2030)

13.4.6.2. Market Revenue and Forecast, by Lung Cancer (2017-2030)

13.4.6.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.4.6.4. Market Revenue and Forecast, by Type of Molecule (2017-2030)

13.4.7. Market Revenue and Forecast, by Drug Class (2017-2030)

13.4.8. North Africa

13.4.8.1. Market Revenue and Forecast, by Therapy (2017-2030)

13.4.8.2. Market Revenue and Forecast, by Lung Cancer (2017-2030)

13.4.8.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.4.8.4. Market Revenue and Forecast, by Type of Molecule (2017-2030)

13.4.9. Market Revenue and Forecast, by Drug Class (2017-2030)

13.4.10. South Africa

13.4.10.1. Market Revenue and Forecast, by Therapy (2017-2030)

13.4.10.2. Market Revenue and Forecast, by Lung Cancer (2017-2030)

13.4.10.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.4.10.4. Market Revenue and Forecast, by Type of Molecule (2017-2030)

13.4.10.5. Market Revenue and Forecast, by Drug Class (2017-2030)

13.4.11. Rest of MEA

13.4.11.1. Market Revenue and Forecast, by Therapy (2017-2030)

13.4.11.2. Market Revenue and Forecast, by Lung Cancer (2017-2030)

13.4.11.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.4.11.4. Market Revenue and Forecast, by Type of Molecule (2017-2030)

13.4.11.5. Market Revenue and Forecast, by Drug Class (2017-2030)

13.5. Latin America

13.5.1. Market Revenue and Forecast, by Therapy (2017-2030)

13.5.2. Market Revenue and Forecast, by Lung Cancer (2017-2030)

13.5.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.5.4. Market Revenue and Forecast, by Type of Molecule (2017-2030)

13.5.5. Market Revenue and Forecast, by Drug Class (2017-2030)

13.5.6. Brazil

13.5.6.1. Market Revenue and Forecast, by Therapy (2017-2030)

13.5.6.2. Market Revenue and Forecast, by Lung Cancer (2017-2030)

13.5.6.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.5.6.4. Market Revenue and Forecast, by Type of Molecule (2017-2030)

13.5.7. Market Revenue and Forecast, by Drug Class (2017-2030)

13.5.8. Rest of LATAM

13.5.8.1. Market Revenue and Forecast, by Therapy (2017-2030)

13.5.8.2. Market Revenue and Forecast, by Lung Cancer (2017-2030)

13.5.8.3. Market Revenue and Forecast, by Distribution Channel (2017-2030)

13.5.8.4. Market Revenue and Forecast, by Type of Molecule (2017-2030)

13.5.8.5. Market Revenue and Forecast, by Drug Class (2017-2030)

Chapter 14. Company Profiles

14.1. AstraZeneca

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. BoehringerIngelheim

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. Bristol-Myers Squibb Company

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. Eli Lilly and Company

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. Hoffmann-La Roche

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. Merck & Co

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. Pfizer Inc.

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. Allergan Inc.

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

14.9. TevaPharmaceutical Industries Ltd.

14.9.1. Company Overview

14.9.2. Product Offerings

14.9.3. Financial Performance

14.9.4. Recent Initiatives

14.10. Abbvie, Inc.

14.10.1. Company Overview

14.10.2. Product Offerings

14.10.3. Financial Performance

14.10.4. Recent Initiatives

14.11. Johnson & Johnson

14.11.1. Company Overview

14.11.2. Product Offerings

14.11.3. Financial Performance

14.11.4. Recent Initiatives

14.12. Amgen Inc.

14.12.1. Company Overview

14.12.2. Product Offerings

14.12.3. Financial Performance

14.12.4. Recent Initiatives

14.13. Novartis AG

14.13.1. Company Overview

14.13.2. Product Offerings

14.13.3. Financial Performance

14.13.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms

Contact Us:

Precedence Research

Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada

Call: +1 774 402 6168

Email: sales@precedenceresearch.com

Website: https://www.precedenceresearch.com

 Blog: https://www.pharma-geek.com